Hospitalizations involving fungal infections increased 8.5% each year in the United States during 2019-2021. During 2020-2021, patients hospitalized with COVID-19-associated fungal infections had higher (48.5%) in-hospital mortality rates than those with non-COVID-19-associated fungal infections (12.3%). Improved fungal disease surveillance is needed, particularly during respiratory virus pandemics.
Keywords: COVID-19; Pneumocystis; SARS; SARS-CoV-2; United States; aspergillosis; blastomycosis; candidiasis; coccidioidomycosis; coronavirus; coronavirus disease; cryptococcosis; fungi; histoplasmosis; hospitalizations; international classification of diseases; invasive fungal infections; mucormycosis; mycoses; pneumonia; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.